NCT00971243 - Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

448

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

MP-513 Lowest Dose and Metformin

MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

DRUG

MP-513 Low Dose and Metformin

MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

DRUG

MP-513 Medium Dose and Metformin

MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

DRUG

MP-513 High Dose and Metformin

MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

DRUG

Placebo and Metformin

Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

Trial Locations (44)

Unknown

Aalborg

Ballerup Municipality

Vejle

Falkensee

Hamburg

Karlsruhe

Kiel

Ludwigshafen

Lübeck

Mainz

Ádám

Békéscsaba

Budapest

Gyöngyös

Kaposvár

Miskolc

Nyíregyháza

Semmelweis

Szentes

Szigetvár

Kaunas

Klaipėda

Vilnius

Gdansk

Krakow

Leszno

Lodz

Niemodlin

Płock

Warsaw

Wroclaw

Brasov

Bucharest

Galati

Ploieşti

Timișoara

Timuș

Addlestone

Ayr

Bournemouth

East Sussex

Edinburgh

Oldham

York